UA118668C2 - Сполука складного ефіру гуанідинобензойної кислоти - Google Patents

Сполука складного ефіру гуанідинобензойної кислоти

Info

Publication number
UA118668C2
UA118668C2 UAA201509922A UAA201509922A UA118668C2 UA 118668 C2 UA118668 C2 UA 118668C2 UA A201509922 A UAA201509922 A UA A201509922A UA A201509922 A UAA201509922 A UA A201509922A UA 118668 C2 UA118668 C2 UA 118668C2
Authority
UA
Ukraine
Prior art keywords
acid ester
trypsin
guanidinobenzoic acid
drugs
kidney disease
Prior art date
Application number
UAA201509922A
Other languages
English (en)
Inventor
Дзіро Фудзіясу
Тору АСАНО
Сусуму Ямакі
Осаму Канеко
Юка Коіке
Томоесі Імаізумі
Ясухару УРАНО
Томокі Сатоу
Сатосі Сасамура
Original Assignee
Такеда Фармасьютікал Компані Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютікал Компані Лімітед filed Critical Такеда Фармасьютікал Компані Лімітед
Publication of UA118668C2 publication Critical patent/UA118668C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Проблема Надати сполуку, яку можна використовувати як засіб для запобігання і/або лікування захворювань нирок. Засіб вирішення Автори даного винаходу вивчали сполуки, які мають інгібуючу трипсин активність, і підтвердили, що сполука складного ефіру гуанідинобензойної кислоти має інгібуючу трипсин активність, тим самим виконавши даний винахід. Сполуку складного ефіру гуанідинобензойної кислоти за даним винаходом можна використовувати як засіб для запобігання і/або лікування захворювань нирок (наприклад, хронічна ниркова недостатність, гострий гломерулонефрит, гостре ушкодження нирок і т. п.), як засіб, що заміщує терапію низькобілковою дієтою, і/або як засіб для запобігання і/або лікування пов'язаних із трипсином захворювань (наприклад, хронічний панкреатит, гастроезофагеальна рефлексна хвороба, печінкова енцефалопатія, грип і т. п.).
UAA201509922A 2013-03-13 2014-03-13 Сполука складного ефіру гуанідинобензойної кислоти UA118668C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013050011 2013-03-13
PCT/JP2014/056601 WO2014142219A1 (ja) 2013-03-13 2014-03-13 グアニジノ安息香酸エステル化合物

Publications (1)

Publication Number Publication Date
UA118668C2 true UA118668C2 (uk) 2019-02-25

Family

ID=51536870

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201509922A UA118668C2 (uk) 2013-03-13 2014-03-13 Сполука складного ефіру гуанідинобензойної кислоти

Country Status (30)

Country Link
US (1) US9969709B2 (uk)
EP (1) EP2975023B1 (uk)
JP (1) JP6314129B2 (uk)
KR (1) KR102145649B1 (uk)
CN (1) CN105051008B (uk)
AU (1) AU2014230583B2 (uk)
BR (1) BR112015022762B1 (uk)
CA (1) CA2905606C (uk)
CY (1) CY1120552T1 (uk)
DK (1) DK2975023T3 (uk)
ES (1) ES2684045T3 (uk)
HK (1) HK1216246A1 (uk)
HR (1) HRP20181371T1 (uk)
HU (1) HUE039526T2 (uk)
IL (1) IL241541B (uk)
LT (1) LT2975023T (uk)
MX (1) MX2015012604A (uk)
MY (1) MY194604A (uk)
PH (1) PH12015502023B1 (uk)
PL (1) PL2975023T3 (uk)
PT (1) PT2975023T (uk)
RS (1) RS57568B1 (uk)
RU (1) RU2661895C2 (uk)
SG (2) SG11201507411TA (uk)
SI (1) SI2975023T1 (uk)
TR (1) TR201809418T4 (uk)
TW (1) TWI666196B (uk)
UA (1) UA118668C2 (uk)
WO (1) WO2014142219A1 (uk)
ZA (1) ZA201506745B (uk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142219A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 グアニジノ安息香酸エステル化合物
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2018080109A (ja) * 2015-03-16 2018-05-24 武田薬品工業株式会社 治療剤
WO2016158788A1 (ja) * 2015-03-27 2016-10-06 武田薬品工業株式会社 縮合複素環化合物
CN105218289B (zh) * 2015-10-15 2017-08-01 浙江大学 一种不饱和脂肪酸原位加氢脱羧制备长链烷烃的方法
KR20200075867A (ko) 2017-11-02 2020-06-26 우베 고산 가부시키가이샤 단백 분해 효소의 쌍두형 저해제

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5289640A (en) 1976-01-21 1977-07-27 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivatives, and antiplasmin agents and remedies for pancreas diseases containing the said guanidinobensolc acid deriv atives
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
JPS5753454A (en) 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
JP2886586B2 (ja) 1989-12-28 1999-04-26 雪印乳業株式会社 新規グアニジノ安息香酸誘導体及びその酸付加塩
US5116985A (en) 1989-12-28 1992-05-26 Snow Brand Milk Products Co., Ltd. Isoquinoline derivatives and salts thereof
JPH0446148A (ja) 1990-06-08 1992-02-17 Asahi Chem Ind Co Ltd ４―グアニジノ安息香酸フェニルエステル誘導体およびそれらを含有する蛋白分解酵素阻害剤
JPH06192085A (ja) 1992-08-31 1994-07-12 Yuji Inada ダニアレルギー治療剤
EP0673924A4 (en) 1992-12-10 1996-04-24 Teikoku Chem Ind Co Ltd PROPRIONIC ACID DERIVATIVE.
JPH0753500A (ja) 1993-08-16 1995-02-28 Sanwa Kagaku Kenkyusho Co Ltd グアニジノ安息香酸誘導体及びこれらを有効成分とする蛋白分解酵素阻害剤
JPH0848664A (ja) * 1994-08-05 1996-02-20 Hisamitsu Pharmaceut Co Inc 新規なグアニジノ安息香酸エステル誘導体
JPH09124571A (ja) * 1995-11-01 1997-05-13 Japan Tobacco Inc アミド化合物及びその用途
KR20000005312A (ko) * 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 트립타아제 억제제 및 신규 구아니디노 유도체
JPH10101556A (ja) 1996-09-27 1998-04-21 Ono Pharmaceut Co Ltd ファクターｄ阻害剤
JPH10251239A (ja) 1997-03-14 1998-09-22 Mochida Pharmaceut Co Ltd 新規４ｈ−３，１−ベンゾオキサジン−４−オン誘導体
JPH10306025A (ja) * 1997-05-07 1998-11-17 Touin Yokohama Univ 花粉プロテアーゼ阻害剤
US7671057B2 (en) 2004-11-08 2010-03-02 Ono Pharmaceutical Co., Ltd. Therapeutic agent for type II diabetes comprising protease-inhibiting compound
WO2006050999A2 (en) 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
EP1811865B1 (en) 2004-11-26 2008-07-16 N.V. Nutricia Infant nutrition with protease inhibitor
WO2006083781A1 (en) 2005-01-31 2006-08-10 Merck & Co., Inc. Antidiabetic bicyclic compounds
AU2007208495A1 (en) 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Hydroxyalkylarylamide derivatives
ES2575131T3 (es) 2007-12-03 2016-06-24 Obe Therapy Biotechnology Inhibidores boropéptidos de enteropeptidasa y sus usos en tratamientos de obesidad, sobrepeso y/o enfermedades asociadas con un metabolismo anormal de la grasa
CN102822154B (zh) * 2009-12-07 2016-06-01 味之素株式会社 杂芳基羧酸酯衍生物
EP2725016B1 (en) 2011-06-07 2016-12-21 EA Pharma Co., Ltd. Heterocyclic carboxylic acid ester derivative
JP6048409B2 (ja) * 2011-09-15 2016-12-21 アステラス製薬株式会社 グアニジノ安息香酸化合物
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
EP4215205A1 (en) 2013-01-03 2023-07-26 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法
WO2014142219A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 グアニジノ安息香酸エステル化合物
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) * 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound

Also Published As

Publication number Publication date
JP6314129B2 (ja) 2018-04-18
MX2015012604A (es) 2016-10-13
TW201522291A (zh) 2015-06-16
ZA201506745B (en) 2017-04-26
RU2015143562A (ru) 2017-04-19
SG10201707504VA (en) 2017-10-30
KR20150130392A (ko) 2015-11-23
CA2905606C (en) 2021-03-09
EP2975023A1 (en) 2016-01-20
PH12015502023A1 (en) 2016-01-18
MY194604A (en) 2022-12-06
EP2975023B1 (en) 2018-05-30
BR112015022762A2 (pt) 2017-07-18
PL2975023T3 (pl) 2018-11-30
TR201809418T4 (tr) 2018-07-23
TWI666196B (zh) 2019-07-21
EP2975023A4 (en) 2016-08-03
CN105051008A (zh) 2015-11-11
RU2661895C2 (ru) 2018-07-23
HK1216246A1 (zh) 2016-10-28
CY1120552T1 (el) 2019-07-10
AU2014230583A1 (en) 2015-10-01
CA2905606A1 (en) 2014-09-18
US20160031847A1 (en) 2016-02-04
HUE039526T2 (hu) 2019-01-28
IL241541B (en) 2019-06-30
ES2684045T3 (es) 2018-10-01
RS57568B1 (sr) 2018-10-31
AU2014230583B2 (en) 2017-09-28
HRP20181371T1 (hr) 2018-10-19
SG11201507411TA (en) 2015-10-29
US9969709B2 (en) 2018-05-15
BR112015022762B1 (pt) 2022-08-16
SI2975023T1 (sl) 2018-10-30
DK2975023T3 (en) 2018-08-20
JPWO2014142219A1 (ja) 2017-02-16
LT2975023T (lt) 2018-08-10
PH12015502023B1 (en) 2016-01-18
CN105051008B (zh) 2018-05-29
KR102145649B1 (ko) 2020-08-18
BR112015022762A8 (pt) 2018-01-23
WO2014142219A1 (ja) 2014-09-18
PT2975023T (pt) 2018-07-27

Similar Documents

Publication Publication Date Title
PH12015502023A1 (en) Guanidinobenzoic acid ester compound
MX362948B (es) Compuesto del ácido guanidinobenzoico.
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
FR2960542B1 (fr) Peptide en tant que medicament, en particulier pour le traitement du cancer
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
MX2015005948A (es) Polipeptidos para transporte de barrera hematoencefalica.
CO7160102A2 (es) Fármaco para prevenir y/o tratar la enfermedad renal poliquística
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
MX2016012318A (es) Compuesto amidico.
HK1223031A1 (zh) 用於降低慢性腎病患者的心力衰竭的枸櫞酸鐵
IL271212A (en) Methods for treating excess blood fat in diabetic patients by administering a pcsk9 inhibitor
IL241305B (en) A pharmaceutical preparation for the treatment of a blood clotting disease containing a therapeutic amount of a preparation containing adamts13
PH12015500434A1 (en) Combination of sglt2 inhibitors and anti-hypertensive drugs
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
EA201390616A1 (ru) ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
BR112017007031A2 (pt) composição farmacêutica para administração subcutânea, método de tratamento de um paciente que sofre de um trauma ou doença de coagulação de sangue, kit de peças, e forma de dosagem de uma composição farmacêutica
MX2015015742A (es) Formula farmaceutica para el tratamiento de afecciones que involucran al sistema venoso y linfatico, al sobrepeso y la obesidad.
CL2009000589A1 (es) Combinacion farmaceutica que comprende un derivado de carbostirilo, o una sal del mismo, y carnitina, o una sal de la misma; medicamento que comprende la combinacion; y uso de la combinacion para tratar la enfermedad arterial periferica oclusiva y el infarto cerebral.
ZA201303220B (en) Stable pharmaceutical composition of a benzimidazole proton pump inhibitor and method for the preparation thereof
TH156277A (th) การรักษามะเร็งด้วยตัวยับยั้ง tor ไคเนส
TH163132A (th) อนุพันธ์เบนซิแลมีนที่เป็นตัวยับยั้งแคลลิครีนในพลาสมา
LV14615A (lv) Līdzeklis karbonila olbaltumvielu līmeņa pazemināšanai asins plazmā